Imidazole antifungal
Ketoconazole
Brand names: Nizoral
Adult dose
Dose: Topical 2% shampoo: twice weekly. Oral systemic restricted (Cushing's only): refer to specialist
Route: Topical/PO
Frequency: varies
Clinical pearls
- Topical: seborrhoeic dermatitis, dandruff, pityriasis versicolor
- Oral: severely restricted to Cushing's syndrome 2nd-line (MHRA/EMA suspension for fungal infections due to hepatotoxicity)
Contraindications
- Acute or chronic liver disease (oral)
- Pregnancy/breastfeeding (oral)
- Concurrent QT-prolonging drugs (oral)
- Concurrent simvastatin/lovastatin (oral)
Side effects
- Topical: local irritation
- Oral (rarely used): severe hepatotoxicity, adrenal suppression, QT prolongation, gynaecomastia
Interactions
- Many CYP3A4 (oral) — refer BNF
- Statins
- Warfarin
- Tacrolimus
Monitoring
- LFTs (oral)
- Cortisol (oral, Cushing's)
Reference: BNF; MHRA Drug Safety Update 2013; https://bnf.nice.org.uk/drugs/ketoconazole/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023